

## EPARTMENT OF COMMERCE UNITED STATE United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

	APPLICATION NO.	FILING DATE	FIRST NAMED INVENTO	OR	ATTO	DRNEY DOCKET NO.	
	09/612,38	07/07/	00 BIGG		D		
Г				7 [	EXAI	MINER	
			HM12/0807				
	CHARLES A MUSERLIAN			<b>,</b>	KIFLE B		
	C/O BIERM	IAN MUSERLI	AN AND LUCAS		ART UNIT	PAPER NUMBER	
	600 THIRD	AVENUE				11	
	NEW YORK	NY 10016			1624	11	
					DATE MAILED:	• •	
						08/07/01	

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trad marks

## Office Action Summary

Application No. 09/612,382

Applied it(s)

, ipp://orania

Examiner

**Bruck Kifle** 

Art Unit

Bigg et al.



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on Jul 18, 2001 2b) This action is non-final. 2a) X This action is FINAL. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213. Disposition of Claims 4) X Claim(s) <u>5-8 and 18-24</u> is/are pending in the application. 4a) Of the above, claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) X Claim(s) 5-8 and 18-24 is/are rejected. 7) Claim(s) is/are objected to. are subject to restriction and/or election requirement. 8) L Claims Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on \_\_\_\_\_\_ is/are objected to by the Examiner. 11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved. 12) The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d). a)  $\square$  All b)  $\square$  Some\* c)  $\square$  None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). \*See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e). Attachment(s) 15) Notice of References Cited (PTO-892) 18) Interview Summary (PTO-413) Paper No(s). 16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 19) Notice of Informal Patent Application (PTO-152) 20) Other: 17) Information Disclosure Statement(s) (PTO-1449) Paper No(s).

Art Unit: 1624

Applicant's amendments and remarks filed 7/18/01 have been received and reviewed.

Claims 5-8 and 18-24 are now pending in this application.

## Claim Rejections - 35 USC § 112

Claims 18-24 are again rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The basis of this rejection is the same as given in the previous office action and is incorporated herein fully by reference. One skilled in the art cannot say which fragment constitutes an analog of camptothecin and when a given fragment no longer falls under an "analog of camptothecin.". One cannot say whether additional ring fusion is permitted or not, whether a dimer is included or not, whether any of the rings may be opened or not. One cannot say what Applicants intention of an analog is. The nature and number of substituents permitted, if any, is not known. Therefore the metes and bounds of the compound could not be ascertained. Applicants can easily overcome this rejection by incorporating the formula on page 5 of the specification into claim 18.

Also, in claim 18 the seven membered ring has a substituent  $R_2O$ . However, the specification and claims 22 and 23 refer to this group as  $R_pO$ . Appropriate correction is required.

## **Double Patenting**

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686

Application/Control Number: 09/612,382

Art Unit: 1624

F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 5-8 and 18-24 are again rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 13 of U.S. Patent No. 5,981,542. Although the conflicting claims are not identical, they are not patentably distinct from each other because the scope of tumors and cancers overlaps. Applicants argue that during the prosecution of US patent number 5,981,542, there was a multiple way restriction, therefore, a double patenting rejection is improper. However, the instant claims overlap with claim 13 and two patents cannot issue to the same subject matter.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37

Art Unit: 1624

CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bruck Kifle whose telephone number is (703) 305-4484.

The fax phone number for this Group is (703) 308-4556 or (703) 305-3592. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-1235.

August 3, 2001

Bruck Kifle
Primary Examiner
Art Unit 1624